Recent advances in type 1 XXXX .

@entity1 @entity6 @entity177 @entity1723 @entity1720 @entity792 @entity413
@entity1723 ( @entity1723 ) is caused by an @entity792 on pancreatic beta cells that leads to @entity1720 . The incidence of @entity1723 in Australia has doubled over the past 20 years. @entity1723 treatment focuses on physiological insulin replacement, aiming for near-normal blood @entity413 levels. Hypoglycaemia is a significant cause of morbidity and mortality in @entity1723 . Optimal @entity1723 management is complex, and is enhanced by empowering individuals in all aspects of managing @entity6 . New technologies, including insulin pumps, continuous @entity413 monitors and sensor-augmented pumps, can assist @entity1 achieve better glycaemic control and reduce the risk of severe hypoglycaemia. @entity1 with @entity1723 can achieve significantly better outcomes during pregnancy and for their @entity1 by planning for their pregnancy and by intensive glycaemic control. Several trials are underway that seek to identify the determinants of autoimmunity and to develop therapies that prevent @entity1723 in at-risk individuals. Pancreatic and islet cell transplants are proven therapies, but are only offered to individuals with @entity6 and @entity177 (pancreas) or severe hypoglycaemia unawareness (islet cell transplants). Although @entity1723 is still associated with considerable premature mortality, recent findings show that a significant improvement in life expectancy has occurred.
